- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment
- Interventions
- florbetapir F 18
- Drug
- Lead sponsor
- Avid Radiopharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Costa Mesa, California + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 116
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Mild Cognitive Impairment (MCI)
- Interventions
- Levetiracetam 62.5mg, Levetiracetam 125mg, Levetiracetam 250mg, Placebo
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Early Alzheimers Disease
- Interventions
- buntanetap/posiphen, Placebo
- Drug
- Lead sponsor
- Annovis Bio Inc.
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 760 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 78
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 72 more
- Conditions
- Mild Cognitive Impairment (MCI), Alzheimer Disease (AD), Dementia With Lewy Bodies (DLB), Frontotemporal Lobar Degeneration (FTLD), Parkinsons Disease With Dementia (PDD), Transient Epileptic Amnesia (TEA), Temporal Lobe Epilepsy (TLE), Spinocerebellar Ataxias (SCA), HIV Associated Neurocognitive Disorder (HAND), Amyotrophic Lateral Sclerosis (ALS), Primary Lateral Sclerosis (PLS)
- Interventions
- Neuraceq
- Other
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Alzheimers Disease
- Interventions
- No Intervention
- Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 80,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2035
- U.S. locations
- 68
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 60 more
- Conditions
- Alzheimer Disease
- Interventions
- sabirnetug, Placebo
- Drug
- Lead sponsor
- Acumen Pharmaceuticals
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 542 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 44
- States / cities
- Carlsbad, California • Fullerton, California • Irvine, California + 40 more
- Conditions
- Alzheimer Disease, Cognitive Dysfunction, Mild Cognitive Impairment, Mild Dementia, Cognitive Decline, Dementia, Alzheimer Type
- Interventions
- Renew NCP-5
- Device
- Lead sponsor
- Renew Research, LLC
- Other
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Irvine, California • Lady Lake, Florida + 7 more
- Conditions
- Mild Traumatic Brain Injury, Moderate Traumatic Brain Injury, Mild Cognitive Impairment
- Interventions
- No Intervention is used for this study but all subjects will be asked to complete electroencephalogram (EEG) testing and an MRI scan., No intervention is used for this study but all subjects will be asked to complete a venous blood draw procedure and a lumbar puncture procedure.
- Device · Procedure
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 30 Years to 90 Years
- Enrollment
- 800 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Alzheimer Disease
- Interventions
- florbetapir F 18
- Drug
- Lead sponsor
- Avid Radiopharmaceuticals
- Industry
- Eligibility
- 35 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 3
- States / cities
- West Palm Beach, Florida • North East, Maryland • Clementon, New Jersey
- Conditions
- Alzheimer's Disease
- Interventions
- ABBV-8E12, placebo for ABBV-8E12
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 453 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 38
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Irvine, California + 31 more
- Conditions
- Alzheimer Disease (AD), Mild Cognitive Impairment (MCI)
- Interventions
- Metronome
- Other
- Lead sponsor
- Boston University Charles River Campus
- Other
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Dementia, Early Onset, Alzheimer Dementia (AD), Mild Cognitive Impairment (MCI), Memory Loss
- Interventions
- Blood draw, Neurocognitive testing, Medical questionnaire
- Genetic · Other
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 35 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Demyelinating Disorders, MCI, Alzheimer's Disease (AD), MS (Multiple Sclerosis), SCI - Spinal Cord Injury, Spinal Radiculopathy
- Interventions
- [ 18F]3F4AP, [18F]MK6240, [11C]PIB
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Amnestic Mild Cognitive Impairment, Alzheimer's Disease
- Interventions
- Insulin (Humulin® R U-100), Placebo
- Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Irvine, California • New Haven, Connecticut + 18 more
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment
- Interventions
- low carbohydrate/high fat diet, low fat/high carbohydrate diet
- Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Alzheimer's Disease
- Interventions
- ALZT-OP1a, ALZT-OP1b, Placebo ALZT-OP1a, Placebo ALZT-OP1b
- Drug · Other
- Lead sponsor
- AZTherapies, Inc.
- Industry
- Eligibility
- 55 Years to 79 Years
- Enrollment
- 620 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 69
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 56 more
- Conditions
- Alzheimer's Disease, Vascular Dementia, Dementia, Memory Impairment
- Interventions
- Metformin, Placebos
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Alzheimers Disease
- Interventions
- Trontinemab, Placebo
- Drug · Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 1,101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Sun City, Arizona • Irvine, California + 31 more
- Conditions
- Alzheimer s Disease
- Interventions
- VY1706 Low dose, VY1706 Mid dose, VY1706 High Dose, Anti-AAV9 Total Antibody (TAb) Assay
- Drug · Device
- Lead sponsor
- Voyager Therapeutics
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Maitland, Florida
- Conditions
- Alzheimer Disease
- Interventions
- PQ912, Placebo
- Drug · Other
- Lead sponsor
- Vivoryon Therapeutics N.V.
- Industry
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Chula Vista, California + 19 more
- Conditions
- Alzheimer's Disease (AD), Mild Cognitive Impairment (MCI), Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
- Interventions
- ATTN201 Focused Ultrasound to the CMN, ATTN201 Unfocused Ultrasound
- Device
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Cognitive Dysfunction, Alzheimer Disease, Blood-Brain Barrier, Apolipoprotein E, Deficiency or Defect of, Brain Aging, Fatty Acids, Omega-3
- Interventions
- Alpha-Linolenic Acid (2.6 g/day), Placebo Control Group
- Drug · Dietary Supplement
- Lead sponsor
- Michal Schnaider Beeri, Ph.D.
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Mild Cognitive Impairment, MCI, Aging, Alzheimer's Disease, AD
- Interventions
- Methylene Blue, FD&C Blue # 2, Phenazopyridine hydrochloride
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 45 Years to 89 Years
- Enrollment
- 117 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2023
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment, Vascular Dementia, Fronto-temporal Dementia, Primary Progressive Aphasia, Parkinson' Disease Dementia, Mixed Dementia
- Interventions
- Not listed
- Lead sponsor
- Exonhit
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 3
- States / cities
- Las Vegas, Nevada • Cleveland, Ohio • Lakewood, Ohio